Handle the flu season
with automated testing
on the spot

Syndromic testing with mariPOC enables simultaneous diagnosis of COVID-19, RSV, influenza and more.

instagram icon
twitter icon
dribbble icon
Pharmacy and test vertical icons-01

mariPOC is getting more readily available, as settling in pharmacies!

mariPOC enables pharmacies to offer easily accessible and affordable professional flu testing for patients and employers.

ArcDia International Ltd

ArcDia develops and manufactures high quality diagnostic products especially for multianalyte and rapid diagnosis of acute infections.

Our goal is to improve healthcare processes, for example, in the treatment of respiratory infections, pharyngitis and intestinal infections.

Antigen tests for professional use

The mariPOC rapid tests, which identify several pathogens at once, are best suited for decentralized diagnostics, such as point-of-care testing in health centres, private clinics, as well as hospital emergency departments.

Fast and comprehensive testing guarantees correct diagnosis without delay.

Read more

tests icon
mariPOC analyzer graphics

Automated test system

The mariPOC test system enables rapid and accurate diagnosis in acute infections. Multiple pathogens are tested from a single clinical sample simultaneously. The quality of the results is ensured by a sophisticated internal autoverification system.

The easy-to-use test system combines specific antigen detection with a unique diagnostic technology developed in Finland.

Read more

Preparing for the flu season

Not sure if it's COVID-19, influenza or a common cold? Find out with mariPOC Respi+ test! The Respi+ is a broad test panel covering 11 pathogens for syndromic testing of respiratory tract infections. Accurate and fast diagnosis enables optimal treatment and quick isolation measures.

Respi+ test is 10 times more likely to identify the correct pathogen than COVID testing alone.

Read more

flu icon

What our long-term customer say

"mariPOC tests can be used to reliably demonstrate a COVID-19 infection. We use the negative result of the antigen test when planning to end the patient's isolation period."

Suvi-Sirkku Kaukoranta
Docent, chief physician of the laboratory, Vaasa Central Hospital


Read more

Asset 10



Press Release: New Innovation Makes Coronavirus Rapid Testing More Accurate than Laboratory Tests

Turku, March 28, 2024 - The Finnish infectious disease diagnostics device manufacturer, ArcDia Oy, has...


Press release: New scientific reports demonstrate the high accuracy of mariPOC COVID-19 tests in decentralized testing

Turku, Finland, October 24th, 2022 – the Finnish medical device manufacturer ArcDia International Ltd reports...


Nasal sampling and EU RAT list

Nasal sampling and self-sampling with mariPOC During the COVID-19 pandemic, the suitability of nasal sampling...


21.3. - 22.3.2024

Virology days 2024

New mariPOC research results will be published at the National Virology Days in Helsinki on...

23.4. - 26.4.2022

ECCMID 2022, Lisbon, Portugal

ArcDia’s mariPOC team will be present and available for meetings at ECCMID2022 in Lisbon April 23rd...

3.9. - 6.9.2021


Come meet us at NSCMID conference 2021 (3rd- 6th September, Turku)! Our team will be...

Get the latest news from ArcDia!

We send around 5 newsletters a year to keep you up-to-date on our latest news.